UK markets open in 5 hours 23 minutes
  • NIKKEI 225

    28,724.02
    +92.57 (+0.32%)
     
  • HANG SENG

    29,885.31
    +437.46 (+1.49%)
     
  • CRUDE OIL

    52.23
    -0.04 (-0.08%)
     
  • GOLD FUTURES

    1,854.80
    -1.40 (-0.08%)
     
  • DOW

    30,996.98
    -179.02 (-0.57%)
     
  • BTC-GBP

    23,955.75
    -3.18 (-0.01%)
     
  • CMC Crypto 200

    670.06
    +60.07 (+9.85%)
     
  • ^IXIC

    13,543.06
    +12.15 (+0.09%)
     
  • ^FTAS

    3,786.06
    -16.24 (-0.43%)
     

Medios AG: Planned takeover of Cranach Pharma GmbH approved by Cartel Office

·3-min read

DGAP-News: Medios AG / Key word(s): Takeover
21.12.2020 / 12:19
The issuer is solely responsible for the content of this announcement.

Press Release

Medios AG: Planned takeover of Cranach Pharma GmbH approved by Cartel Office

Berlin, 21 December 2020 - The German Federal Cartel Office has approved Medios AG's intended takeover of the specialized pharmaceutical wholesaler Cranach Pharma GmbH, Hamburg, on 21 December 2020.

Medios AG had concluded a purchase agreement with BMSH GmbH for the takeover of Cranach Pharma GmbH on 26 November 2020. The merger will create the largest Specialty Pharma provider in Germany with group sales of well over €1bn in the 2021 financial year.

The closing of the transaction is planned for the first quarter of 2021.

-------------------

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients, GMP-certified provider of patient-specific therapies and innovative analytical methods, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. In the field of drug safety, NIR spectroscopic analysis methods (NIR: Near infrared) are used to distinguish marketable finished drugs from drug counterfeits. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8, DE000A288821) are listed in the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). The Company is listed in the SDAX selection index.

Contact
Claudia Nickolaus
Head of Investor & Public Relations
Medios AG
Heidestraße 9 | 10557 Berlin | Germany
P +49 30 232 566 800
c.nickolaus@medios.ag
www.medios.ag

Nikolaus Hammerschmidt
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg | Germany
P +49 40 609 186 18
nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.


21.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Medios AG

Heidestraße 9

10557 Berlin

Germany

Phone:

+49 30 232 566 - 800

Fax:

+49 30 232 566 - 801

E-mail:

ir@medios.ag

Internet:

www.medios.ag

ISIN:

DE000A1MMCC8

WKN:

A1MMCC

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf

EQS News ID:

1156353


 

End of News

DGAP News Service

show this
show this